Menu
Recruiting NCT07160153

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

— Observational Cannabis Dependence Harmful Use Cognitive Assessment

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Neurocognitive assessment, Urine toxicological assessment.
Who it may be relevant to
Registry conditions: Cannabis Dependence, Harmful Use, Cognitive Assessment. Basic parameters: 15 years — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Czechia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Detailed description

Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.

Interventions

  • Diagnostic test Neurocognitive assessment
    Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)
  • Diagnostic test Urine toxicological assessment
    Urine toxicological assessment

Primary outcome measures

  • Change in performance TMT-B [Time frame: 8 weeks]
Secondary outcome measures (4)
  • Change in performance on AVLT [Time frame: 8 weeks]
  • Change in performance on the Stroop Test [Time frame: 8 weeks]
  • Change in performance on the Tower of London [Time frame: 8 weeks]
  • Change in performance on CPT-IP [Time frame: 8 weeks]

Eligibility criteria

Inclusion criteria

  • Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion criteria

  • psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
  • somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
  • Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Czechia · 1 center
  • University Hospital Pilsen — Pilsen

Identifiers

NCT: NCT07160153 · CANAA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗